JP2020522555A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522555A5 JP2020522555A5 JP2019567709A JP2019567709A JP2020522555A5 JP 2020522555 A5 JP2020522555 A5 JP 2020522555A5 JP 2019567709 A JP2019567709 A JP 2019567709A JP 2019567709 A JP2019567709 A JP 2019567709A JP 2020522555 A5 JP2020522555 A5 JP 2020522555A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- icos
- binding portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090001123 antibodies Proteins 0.000 claims description 125
- 102000004965 antibodies Human genes 0.000 claims description 125
- 239000000427 antigen Substances 0.000 claims description 104
- 108091007172 antigens Proteins 0.000 claims description 104
- 102000038129 antigens Human genes 0.000 claims description 104
- 201000011510 cancer Diseases 0.000 claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 102100007290 CD274 Human genes 0.000 claims description 11
- 101710012053 CD274 Proteins 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims description 6
- 201000011231 colorectal cancer Diseases 0.000 claims description 6
- 230000003042 antagnostic Effects 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010017758 Gastric cancer Diseases 0.000 claims description 3
- 206010025650 Malignant melanoma Diseases 0.000 claims description 3
- 108010019706 Nivolumab Proteins 0.000 claims description 3
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims description 3
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 201000009030 carcinoma Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 229960003301 nivolumab Drugs 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 108010026276 pembrolizumab Proteins 0.000 claims description 3
- 229960002621 pembrolizumab Drugs 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010061818 Disease progression Diseases 0.000 claims description 2
- 231100000402 unacceptable toxicity Toxicity 0.000 claims description 2
- 239000003814 drug Substances 0.000 description 15
- 229940079593 drugs Drugs 0.000 description 15
- 108010072668 atezolizumab Proteins 0.000 description 14
- 229920000023 polynucleotide Polymers 0.000 description 12
- 239000002157 polynucleotide Substances 0.000 description 12
- 238000001990 intravenous administration Methods 0.000 description 4
- 101700064281 ATP1 Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762517309P | 2017-06-09 | 2017-06-09 | |
| US62/517,309 | 2017-06-09 | ||
| US201862666278P | 2018-05-03 | 2018-05-03 | |
| US62/666,278 | 2018-05-03 | ||
| PCT/IB2018/054167 WO2018225033A1 (en) | 2017-06-09 | 2018-06-08 | Combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020522555A JP2020522555A (ja) | 2020-07-30 |
| JP2020522555A5 true JP2020522555A5 (ru) | 2021-07-26 |
Family
ID=62873504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019567709A Pending JP2020522555A (ja) | 2017-06-09 | 2018-06-08 | 組み合わせ療法 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3634483A1 (ru) |
| JP (1) | JP2020522555A (ru) |
| CN (1) | CN110869049A (ru) |
| BR (1) | BR112019025325A2 (ru) |
| CA (1) | CA3066048A1 (ru) |
| WO (1) | WO2018225033A1 (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019002529A2 (pt) | 2016-08-09 | 2019-05-28 | Kymab Ltd | anticorpo isolado, composição, método para modular o equilíbrio de células t, método para tratar uma doença ou afecção tratável com terapia, método para tratar câncer, combinação de anticorpo igg1, anticorpo anti-icos, mamífero não humano transgênico, e método para produzir um anticorpo |
| US11629189B2 (en) | 2017-12-19 | 2023-04-18 | Kymab Limited | Bispecific antibody for ICOS and PD-L1 |
| US20230149543A1 (en) * | 2020-04-14 | 2023-05-18 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer based upon an icos antbody and a pd-l1 antibody tgf-bets-receptor fusion protein |
| WO2021209357A1 (en) * | 2020-04-14 | 2021-10-21 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
| JP4488740B2 (ja) | 2001-11-13 | 2010-06-23 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 免疫細胞活性化を調節する作用剤およびその使用方法 |
| ES2654064T3 (es) | 2002-07-03 | 2024-03-13 | Ono Pharmaceutical Co | Composiciones inmunopotenciadoras que comprenden anticuerpos anti-PD-L1 |
| EP1576014B1 (en) | 2002-12-23 | 2011-06-29 | Wyeth LLC | Antibodies against pd-1 and uses thereof |
| EP1591527B1 (en) | 2003-01-23 | 2015-08-26 | Ono Pharmaceutical Co., Ltd. | Substance specific to human pd-1 |
| KR101339628B1 (ko) | 2005-05-09 | 2013-12-09 | 메다렉스, 인코포레이티드 | 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| EP2703011A3 (en) | 2007-05-07 | 2014-03-26 | MedImmune, LLC | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| PL2170959T3 (pl) | 2007-06-18 | 2014-03-31 | Merck Sharp & Dohme | Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| CA2735006A1 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
| AU2009290543B2 (en) | 2008-09-12 | 2015-09-03 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| CA2736829C (en) | 2008-09-12 | 2018-02-27 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| JP5933975B2 (ja) | 2008-11-12 | 2016-06-15 | メディミューン，エルエルシー | 抗体製剤 |
| KR20210060670A (ko) | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도 |
| CN102740887B (zh) * | 2009-09-30 | 2015-04-15 | 斯隆凯特林防癌纪念中心 | 用于治疗癌症的组合免疫疗法 |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2011066389A1 (en) | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Targeted binding agents against b7-h1 |
| US20110280877A1 (en) | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
| CN101898945B (zh) | 2010-07-27 | 2013-05-08 | 大连理工大学 | 盐析萃取发酵液中丙酮和丁醇的方法 |
| SG193428A1 (en) | 2011-03-31 | 2013-10-30 | Inst Nat Sante Rech Med | Antibodies directed against icos and uses thereof |
| PE20141693A1 (es) | 2011-08-01 | 2014-11-24 | Genentech Inc | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1e inhibidores de mek |
| CA2856895C (en) | 2011-11-28 | 2021-10-26 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
| CN104470949A (zh) | 2012-05-15 | 2015-03-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| AU2013278843A1 (en) * | 2012-06-21 | 2014-03-27 | Compugen Ltd. | LSR antibodies, and uses thereof for treatment of cancer |
| ES2684552T3 (es) | 2012-09-03 | 2018-10-03 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos dirigidos contra ICOS para tratar la enfermedad de injerto contra hospedador |
| CN107892719B (zh) | 2012-10-04 | 2022-01-14 | 达纳－法伯癌症研究所公司 | 人单克隆抗-pd-l1抗体和使用方法 |
| WO2015019284A2 (en) * | 2013-08-05 | 2015-02-12 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| PT3273992T (pt) | 2015-03-23 | 2020-08-21 | Jounce Therapeutics Inc | Anticorpos para icos |
| EP3331919A1 (en) * | 2015-08-07 | 2018-06-13 | GlaxoSmithKline Intellectual Property Development Limited | Combination therapy comprising anti ctla-4 antibodies |
-
2018
- 2018-06-08 WO PCT/IB2018/054167 patent/WO2018225033A1/en active Application Filing
- 2018-06-08 CN CN201880044500.1A patent/CN110869049A/zh active Pending
- 2018-06-08 BR BR112019025325-4A patent/BR112019025325A2/pt unknown
- 2018-06-08 EP EP18739638.7A patent/EP3634483A1/en not_active Withdrawn
- 2018-06-08 CA CA3066048A patent/CA3066048A1/en active Pending
- 2018-06-08 JP JP2019567709A patent/JP2020522555A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020522555A5 (ru) | ||
| KR102333658B1 (ko) | 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체 | |
| US9907768B2 (en) | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | |
| JP2017537892A5 (ru) | ||
| JP6283665B2 (ja) | Ｇｄ２陽性癌を治療するための方法 | |
| JP2017537090A5 (ru) | ||
| JP2020529421A (ja) | がんの処置のためのＰＤ−１アンタゴニストおよびベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニストの組み合わせ | |
| JP2017533912A5 (ru) | ||
| US10485775B2 (en) | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | |
| JP2016525117A5 (ru) | ||
| CN110291109A (zh) | 人程序性死亡受体pd-1的单克隆抗体及其片段 | |
| JP2016520082A5 (ru) | ||
| CA2949327A1 (en) | Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers | |
| JP7374765B2 (ja) | 抗ｄｋｋ－１抗体を使用して癌を治療するためのバイオマーカーとしてのベータ－カテニンの使用 | |
| Mendelsohn | Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic | |
| RU2018107693A (ru) | Комбинированные виды лечения и их варианты применения и способы | |
| JP2019524706A5 (ru) | ||
| TW202031291A (zh) | 治療對pd-1/pd-l1傳訊抑制劑無反應的癌症之方法及藥物 | |
| US20220387529A1 (en) | Treatment for primary and metastatic cancer | |
| JP2021504329A5 (ru) | ||
| CN111166878B (zh) | 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途 | |
| CN106963950B (zh) | 用于治疗肿瘤的联合用药物 | |
| WO2024111609A1 (ja) | Ｋｒａｓ変異型がん治療剤 | |
| US20220064304A1 (en) | Methods of treating cancer pain by administering a pd-1 inhibitor | |
| Conn | Recent developments in oncology immunotherapy, implications for NPs part 1 |